This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AbbVie Announces Market Availability Of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules For Patients With Exocrine Pancreatic Insufficiency

NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON ® (pancrelipase) Delayed-Release Capsules is commercially available in the United States.  The U.S. Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.  This new strength is the highest dose of pancreatic enzyme replacement therapy (PERT) currently available and approved by the FDA.

"Patients with EPI require replacement of enzymes to help them break down food into nutrients," said Dr. David C. Whitcomb, Chief, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh.  "Obtaining adequate lipase doses, however, often means taking a large number of capsules with each meal.  A higher lipase capsule dose is an option for some patients, and it may help reduce the number of capsules they take when compared to lower lipase products."

Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to produce enzymes that help in the digestion of food.  Patients living with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions may develop EPI.  Symptoms of EPI may include steatorrhea (foul-smelling, greasy stools), gas, bloating, stomach pain, frequent bowel movements and weight loss.  Pancreatic enzymes work directly in the small intestines to help break down fats, proteins and carbohydrates, allowing the body to better digest the nutrients from food.

"We are pleased to be able to offer healthcare professionals increased choices in dosing options for their patients," said Maria Rivas, M.D., vice president, Global Medical Affairs, AbbVie.  "With the launch of this new CREON strength, healthcare professionals and patients now have access to the broadest range of dosage strengths in the PERT class."

UsesCREON ® (pancrelipase) Delayed-Release Capsules is a prescription medicine used to treat people who cannot digest food normally because their pancreas does not make enough enzymes due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

Important Safety InformationCREON may increase the chance of having a rare bowel disorder called fibrosing colonopathy. The risk of having this condition may be reduced by following the dosing instructions given by the doctor.

CREON capsules or the contents of the capsules should not be crushed, chewed, or held in the mouth because this may cause mouth irritation. CREON should always be taken with a meal or snack and enough liquid to swallow CREON completely.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs